Skip to main content

ASCO Highlights

Dostarlimab (Jemperli), an anti–PD-1 monoclonal antibody, demonstrated a 100% clinical complete response rate among 14 patients with mismatch repair-deficient (dMMR) locally advanced rectal cancer, according to the results of a recent clinical trial. Read More ›

Once-daily ibrutinib (Imbruvica) combined with bendamustine (Bendeka) and rituximab (Rituxan; BR) significantly improved progression-free survival (PFS) compared with placebo plus BR in patients aged ≥65 years with newly diagnosed mantle-cell lymphoma (MCL), according to data from the phase 3 SHINE trial. Read More ›

Treatment with acalabrutinib (Calquence) elicited a complete or partial response in more than 50% of patients with relapsed or refractory marginal zone lymphoma (MZL), according to interim results of a phase 2 study presented by L. Elizabeth Budde, MD, PhD, Associate Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

Treatment with nivolumab (Opdivo) plus ipilimumab (Yervoy) in the neoadjuvant setting plus adjuvant nivolumab resulted in a high rate of pathologic complete response (pCR) in patients with resectable microsatellite instable (MSI)/mismatch repair deficient (dMMR) oeso-gastric junction (OGJ) adenocarcinoma, according to findings from the GERCOR NEONIPIGA clinical trial, which were presented by Thierry André, MD, Professor, Medical Oncology, Sorbonne Université, Hôpital Saint Antoine, Paris, France, at the 2022 ASCO Gastrointestinal Cancers Symposium. Read More ›

Pembrolizumab (Keytruda) added to best supportive care (BSC) improved outcomes including overall survival (OS) versus BSC alone in Asian patients with advanced hepatocellular carcinoma (HCC) previously treated with sorafenib (Nexavar), according to final results from the KEYNOTE-394 trial. Read More ›

Trastuzumab deruxtecan (Enhertu; T-DXd) continues to show superior antitumor activity and improved survival compared with standard chemotherapy in patients with advanced HER2-expressing gastric or gastroesophageal junction (GEJ) cancer, according to updated results from the phase 2 DESTINY-Gastric01 trial. Read More ›

nterim results from a phase 2 clinical trial showed that a novel combination of aldoxorubicin, N-803 (an IL-15 superagonist), and PD-L1 natural killer cell therapy (Nant Cancer Vaccine) plus low-dose chemotherapy doubled overall survival (OS) compared with historical controls in patients with locally advanced or metastatic pancreatic cancer. Read More ›

The PD-1/CTLA-4 bispecific antibody, AK104, plus chemotherapy represents a potential new first-line treatment option for patients with advanced gastric or gastroesophageal junction (GEJ) cancer. Read More ›

At the CCA Summit held during the 2021 ASCO Gastrointestinal (GI) Cancers Symposium, Rachna T. Shroff, MD, MS, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, Tucson, discussed 15 clinical trials that were presented at the ASCO GI Cancers Symposium on cholangiocarcinoma (CCA) and hepatobiliary diseases. She highlighted key advances related to chemotherapy, targeted therapies, and biomarkers in the management of biliary tract cancers, including CCA. Read More ›

Results from the ARROW study show that pralsetinib demonstrates broad and durable antitumor activity across multiple advanced solid tumor types, regardless of RET fusion genotype. Read More ›

Page 1 of 4